Diagnostic Histopathology
Volume 14, Issue 1 , Pages 55-59 , January 2008

Tumour heterogeneity and the assessment of expression of proteins for targeted biological therapies

References 

  1. Cross SS. The molecular pathology of new anti-cancer agents. Curr Diagn Pathol. 2005;11:329–339
  2. Dacic S, Finkelstein SD, Yousem SA. Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity. Exp Mol Pathol. 2005;78:135–139
  3. Beckman RA, Loeb LA. Negative clonal selection in tumor evolution. Genetics. 2005;171:2123–2131
  4. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211:286–295
  5. Gong Y, Booser DJ, Sneige N. Comparison of HER2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763–1769
  6. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Br J Cancer. 2004;90:2344–2348
  7. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007;9:R31

PII: S1756-2317(07)00125-9

doi: 10.1016/j.mpdhp.2007.11.007

Diagnostic Histopathology
Volume 14, Issue 1 , Pages 55-59 , January 2008

Article Tools

* Image Usage & Resolution